Key Insights The projected fair value for Viridian Therapeutics is US$14.53 based on 2 Stage Free Cash Flow to Equity... Viridian Therapeutics (VRDN) announced topline data from the THRIVE-2 phase ...

Dec 16 (Reuters) - Viridian Therapeutics' (VRDN.O), opens new tab experimental treatment for chronic thyroid eye disease (TED) significantly reduced symptoms such as double vision and eye bulging ...

10 analysts have expressed a variety of opinions on Viridian Therapeutics VRDN over the past quarter, offering a diverse set of opinions from bullish to bearish. The following table summarizes ...

Viridian Therapeutics (NASDAQ:VRDN) shares shot up 25% in early trading Monday after the company reported positive topline results from a Phase 3 study of its drug veligrotug in the treatment of ...

After proudly introducing you to our latest Czapek × Fratello Promenade Transparencies “Viridian Green” edition, we are now thrilled to launch it ... The shade is created by a metallic coating that ...

Easily identify outperforming stocks and invest smarter with Top Smart Score Stocks Thomas Smith’s rating is based on the promising results from Viridian Therapeutics’ Phase 3 THRIVE-2 study ...

The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...

Pantone has named an “evocative soft brown” its color of the year for 2025, continuing a tradition that has now run for more than a quarter of a century. In a statement published Thursday ...